As the pharma industry steps up its search for stem cell-based therapies and regenerative medicines, Stem Cell Sciences (SCS) is uniquely positioned to meet the growth in demand for cells for research and drug discovery.
A trail-blazer in the field since 1994, SCS specialises in technologies to grow, differentiate and purify embryonic, neural and other tissue-specific stem cells. The pharma industry takes advantage of our patented technologies, proprietary cells, automated processes and services to accelerate their drug discovery programmes and regenerative medicine therapies.
SCS:
- Collaborates on developing methodologies and tools to turn stem cells into differentiated cells of interest
- Automates high volume production of stem cell lines
- Genetically modifies cells for population purification and sub-population identification
- Screens client compounds on stem and differentiated cells
- Provides proprietary cells and culture media
- Licenses SCS’s proprietary portfolio of stem cell technologies
- Fast tracks our customers’ use of stem cells
The Times Newspaper
December 26, 2008
‘Knockout’ rats are created to strike a blow against disease.
We manufacture and deliver:
- Physiologically relevant human cells
- Consistently and at scale
- Adult, foetal and embryonic stem and differentiated cells
We transfer knowledge and license our technologies
Demonstration of iPS technology – from brain to heart
NEW Check out i STEM® our new media which eliminates differentiation signals to sustain mouse ES cell self-renewal and maintain the pure ES cell ground state.
i STEM®, 2i and 3i are registered trademarks of Stem Cell Sciences.
